AbbVie (NYSE:ABBV) Shares Up 2.1% – Time to Buy?

AbbVie Inc. (NYSE:ABBV)’s stock price traded up 2.1% during trading on Friday . The company traded as high as $229.47 and last traded at $227.44. 18,590,959 shares were traded during mid-day trading, an increase of 192% from the average session volume of 6,369,610 shares. The stock had previously closed at $222.82.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Bank of America upped their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Citigroup cut their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Finally, Piper Sandler reissued an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Stock Performance

The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The firm has a market cap of $401.98 billion, a PE ratio of 172.30, a P/E/G ratio of 1.27 and a beta of 0.36. The stock’s 50 day moving average price is $226.70 and its 200 day moving average price is $210.69.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the firm earned $3.00 EPS. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie during the 2nd quarter valued at approximately $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter worth $26,000. Chelsea Counsel Co. bought a new stake in AbbVie during the third quarter valued at $26,000. TD Capital Management LLC raised its holdings in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Finally, Spurstone Advisory Services LLC bought a new position in shares of AbbVie in the 2nd quarter worth about $28,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.